Recruiting
Phase 1
Phase 2

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05078866

Conditions

Lynch Syndrome

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP

Biospecimen Collection

Endoscopic Biopsy

MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP

Questionnaire Administration

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information